Max Hodak maps BCI path to scale

The big signal here is that BCIs are shifting from speculative moonshots to productizable medical systems, but the path to mass adoption still runs through hard clinical, safety, and cost constraints.

• –Science positions PRIMA as a practical near-term BCI: a specific disease target, defined trial endpoints, and a regulatory pathway.
• –Reported reading gains in trial participants make this more than a lab demo, but outcomes still depend on training, device limits, and patient selection.
• –Hodak’s framing suggests the market will expand from therapeutic use cases (vision loss, paralysis) before any enhancement-focused consumer narrative.
• –The interview also surfaces the strategic tension: AI-era ambition is huge, but trust will be won or lost on safety, durability, and reimbursement.